- Home
- TSI vs AVTX Comparison
TSI vs AVTX Comparison
Compare TSI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- AVTX
- Stock Information
- Founded
- TSI 1987
- AVTX 2011
- Country
- TSI United States
- AVTX United States
- Employees
- TSI N/A
- AVTX N/A
- Industry
- TSI Investment Managers
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- AVTX Health Care
- Exchange
- TSI Nasdaq
- AVTX Nasdaq
- Market Cap
- TSI 235.1M
- AVTX 248.3M
- IPO Year
- TSI N/A
- AVTX 2015
- Fundamental
- Price
- TSI $4.93
- AVTX $16.26
- Analyst Decision
- TSI
- AVTX Strong Buy
- Analyst Count
- TSI 0
- AVTX 9
- Target Price
- TSI N/A
- AVTX $30.14
- AVG Volume (30 Days)
- TSI 106.8K
- AVTX 364.7K
- Earning Date
- TSI 01-01-0001
- AVTX 11-07-2025
- Dividend Yield
- TSI 7.46%
- AVTX N/A
- EPS Growth
- TSI N/A
- AVTX N/A
- EPS
- TSI N/A
- AVTX N/A
- Revenue
- TSI N/A
- AVTX $441,000.00
- Revenue This Year
- TSI N/A
- AVTX N/A
- Revenue Next Year
- TSI N/A
- AVTX N/A
- P/E Ratio
- TSI N/A
- AVTX N/A
- Revenue Growth
- TSI N/A
- AVTX N/A
- 52 Week Low
- TSI $4.48
- AVTX $3.39
- 52 Week High
- TSI $4.87
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- TSI 50.02
- AVTX 55.00
- Support Level
- TSI $4.88
- AVTX $16.77
- Resistance Level
- TSI $4.96
- AVTX $18.65
- Average True Range (ATR)
- TSI 0.04
- AVTX 1.60
- MACD
- TSI 0.00
- AVTX -0.17
- Stochastic Oscillator
- TSI 62.50
- AVTX 46.98
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).